Results 61 to 70 of about 180 (117)

Cost-effectiveness of treatment sequences following first-line rituximab in relapsing-remitting multiple sclerosis: a Norwegian microsimulation study

Frontiers in Neurology
BackgroundThe Norwegian guideline recommends highly effective disease-modifying therapies (DMTs) as the first line treatment for multiple sclerosis (MS), with rituximab preferred in clinical practice.
Simone Huygens, Matthijs Versteegh, Pål Berg-Hansen, Stein Henry Bjelland, Trygve Holmøy, Trygve Holmøy, Øivind Torkildsen, Øivind Torkildsen   +7 more
doaj   +1 more source

Oxidative stress and cellular senescence: Roles in tumor progression and therapeutic opportunities

MedComm – Oncology, Volume 3, Issue 4, December 2024.
Cellular senescence is intrinsically related to multiple aspects of tumor development. Oxidative stress contributes to tumor development by regulating cellular senescence. Targeting cellular senescence by modulating oxidative stress can benefit tumor management.
Ping Jin, Xu‐Dong Feng, Cheng‐Shuang Huang, Jia Li, Hui Wang, Xian‐Mei Wang, Lei Li, Lan‐Qing Ma   +7 more
wiley   +1 more source

The gut-brain-axis one year after treatment with cladribine tablets in patients with relapsing remitting multiple sclerosis: a pilot study

Frontiers in Immunology
IntroductionCladribine tablets are an effective treatment for relapsing remitting multiple sclerosis (RRMS). However, almost half of the treated patients are not free of disease activity after two years.
Jeske van Pamelen, Jeske van Pamelen, Carla Rodriguez-Mogeda, Lynn van Olst, Susanne M. A. van der Pol, Maarten L. Boon, Janet de Beukelaar, Oliver H. H. Gerlach, Oliver H. H. Gerlach, Andries E. Budding, Joep Killestein, Helga E. de Vries, Leo H. Visser   +12 more
doaj   +1 more source

Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing–Remitting Multiple Sclerosis Patients? A Narrative Review

Neurology and Therapy, 2020
The majority of disease-modifying drugs (DMDs) available for the management of active relapsing–remitting multiple sclerosis (RMS) depend on continuous drug intake for maintained efficacy, with escalation to a more active drug when an unacceptable level ...
Isa Ahmed AlSharoqi, Mohamed Aljumah, Saeed Bohlega, Cavit Boz, Abdelkader Daif, Salam El-Koussa, Jihad Inshasi, Murat Kurtuncu, Thomas Müller, Chris Retief, Mohammad Ali Sahraian, Vahid Shaygannejad, Ilham Slassi, Karim Taha, Magd Zakaria, Per Soelberg Sørensen   +15 more
doaj   +1 more source

The diagnostic challenge of coexisting systemic lupus erythematosus and multiple sclerosis in a young male: Rare but real

Clinical Case Reports, Volume 12, Issue 11, November 2024.
Key Clinical Message The coexistence of multiple sclerosis (MS) and systemic lupus erythematosus (SLE) is exceptionally rare, especially in males. This case highlights the importance of early diagnosis and treatment with immunomodulatory therapies like rituximab, which can lead to sustained remission in patients with overlapping autoimmune disorders.
Tatiana Charbel, Dany Akiki, Said El Hage, Gaby Moukarzel, Elie Assaf   +4 more
wiley   +1 more source

Prospective observational study to evaluate treatment satisfaction and effectiveness in patients with relapsing multiple sclerosis starting cladribine tablets (CLADREAL) in Italy

Frontiers in Neurology
Disease-modifying therapies (DMTs) for multiple sclerosis (MS) reduce relapse frequency, magnetic resonance imaging (MRI) activity, and slow disability progression.
Massimo Filippi, Massimo Filippi, Massimo Filippi, Massimo Filippi, Massimo Filippi, Laura Ferrè, Chiara Zanetta, Chiara Zanetta, Caterina Rizzi, Gabriella Pessina, Francesco Assogna, Maria A. Rocca, Maria A. Rocca, Maria A. Rocca   +13 more
doaj   +1 more source

Impact of cladribine tablets on PROs in patients with MS: insights from the 1st interim analysis of the CLADFIT-MS study

Frontiers in Neurology
BackgroundCladribine tablets are an oral short-course disease-modifying therapy (DMT) approved for the treatment of highly active relapsing multiple sclerosis (MS).
Giovanna Borriello, Giovanna Borriello, Clara Grazia Chisari, Clara Grazia Chisari, Davide Maimone, Francesca Matta, Massimiliano Mirabella, Massimiliano Mirabella, Damiano Paolicelli, Francesco Assogna, Sandro Caradonna, Francesco Patti, Francesco Patti   +12 more
doaj   +1 more source

Experience with the use of cladribine tablets in real-life clinical practice: independent analysis of data from 12 Russian clinical centres

Неврология, нейропсихиатрия, психосоматика
Multiple sclerosis (MS) is an autoimmune-inflammatory and neurodegenerative disease of the central nervous system. The article analyses the ability of cladribine, which due to its selective lymphotoxic effect on activated cells and central effect on ...
A. N. Boyko, V. M. Alifirova, D. V. Pashkovskaya, E. I. Kuchina, S. A. Sivertseva, E. L. Turova, Z. A. Goncharova, O. Yu. Rudenko, Yu. Yu. Pogrebnova, F. A. Khabirov, T. I. Khaibullin, N. N. Babicheva, N. L. Khoroshilova, O. V. Dzundza, O. A. Soldatova, A. N. Belova, G. Е. Sheiko, A. Е. Makarova, N. G. Glavinskaya   +18 more
doaj   +1 more source

Identifying Cladribine prescription pattern in MS: an Italian multicentre study

Therapeutic Advances in Neurological Disorders
Background: Characterizing Cladribine tablets prescription pattern in daily clinical practice is crucial for optimizing multiple sclerosis (MS) treatment.
Aurora Zanghì, Roberta Fantozzi, Matteo Foschi, Elisabetta Signoriello, Matilde Inglese, Giacomo Lus, Diego Centonze, Andrea Surcinelli, Tommaso Sirito, Simona Bonavita, Carlo Avolio, Emanuele D’Amico   +11 more
doaj   +1 more source

Sustained effects on immune cell subsets and autoreactivity in multiple sclerosis patients treated with oral cladribine

Frontiers in Immunology
IntroductionCladribine tablet therapy is an efficacious treatment for multiple sclerosis (MS). Recently, we showed that one year after the initiation of cladribine treatment, T and B cell crosstalk was impaired, reducing potentially pathogenic effector ...
Rikke Holm Hansen, Marina Rode von Essen, Mie Reith Mahler, Stefan Cobanovic, Finn Sellebjerg, Finn Sellebjerg   +5 more
doaj   +1 more source